Vistin Pharma Q3 2025 slides: Revenue up 3% as metformin production hits record high
PositiveFinancial Markets

Vistin Pharma has reported a 3% increase in revenue for Q3 2025, driven by record-high production of metformin. This growth is significant as it highlights the company's ability to meet rising demand for this essential diabetes medication, showcasing its operational efficiency and market position. Such positive financial results not only reflect the company's strong performance but also contribute to the broader healthcare sector's stability.
— Curated by the World Pulse Now AI Editorial System










